Literature DB >> 10919414

Anaphylaxis in patients with hemophilia.

M Jadhav1, I Warrier.   

Abstract

Anaphylactic reactions are rare emergencies observed in hemophilia patients. In hemophilia (B) (HB) patients they typically occur coincident with the development of an inhibitor. It is important to be aware of the possibility of such reactions, and the patient's family should be educated at the time of initial diagnosis and discussion. Because these reactions typically occur within the first 10 to 20 treatment courses, the first few infusions should be given in a hospital/clinic setting equipped to manage such emergencies. Obtaining the exact genotype may identify the HB patients at risk for this complication. When immune tolerance induction (ITI) is attempted in patients with HB inhibitors and anaphylaxis, the physician should be vigilant in detecting proteinuria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10919414     DOI: 10.1055/s-2000-9824

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  10 in total

1.  Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.

Authors:  Yingyu Chen; Jocelyn A Schroeder; Erin L Kuether; Guowei Zhang; Qizhen Shi
Journal:  Mol Ther       Date:  2013-08-23       Impact factor: 11.454

2.  Anaphylaxis after treatment with recombinant factor VIII: investigation and therapeutic challenge.

Authors:  Sofia Pires; Teresa Sevivas; Carla Chaves Loureiro; Borja Bartholomé
Journal:  BMJ Case Rep       Date:  2018-12-14

Review 3.  Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 4.  Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.

Authors:  David W Scott; Jay N Lozier
Journal:  Br J Haematol       Date:  2011-11-07       Impact factor: 6.998

5.  Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.

Authors:  Anthony K Chan; Jayanthi Alamelu; Chris Barnes; Ampaiwan Chuansumrit; May-Lill Garly; Rikke Medom Meldgaard; Guy Young
Journal:  Res Pract Thromb Haemost       Date:  2020-07-29

6.  Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient.

Authors:  Priya Verghese; Stephen Darrow; Margaret H Kurth; Robyn C Reed; Youngki Kim; Susan Kearney
Journal:  Pediatr Nephrol       Date:  2013-02-06       Impact factor: 3.714

7.  Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity.

Authors:  Jocelyn A Schroeder; Juan Chen; Yingyu Chen; Yuanhua Cai; Hongyin Yu; Jeremy G Mattson; Paul E Monahan; Qizhen Shi
Journal:  Blood Adv       Date:  2021-03-09

8.  Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4.

Authors:  B K Sack; X Wang; A Sherman; G L Rogers; D M Markusic
Journal:  Haemophilia       Date:  2014-11-23       Impact factor: 4.287

Review 9.  Platelet-Targeted Gene Therapy for Hemophilia.

Authors:  Qizhen Shi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-07       Impact factor: 6.698

10.  Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.

Authors:  David M Markusic; Brad E Hoffman; George Q Perrin; Sushrusha Nayak; Xiaomei Wang; Paul A LoDuca; Katherine A High; Roland W Herzog
Journal:  EMBO Mol Med       Date:  2013-09-16       Impact factor: 12.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.